SCHEMBL6124689

SCHEMBL6124689

CCC1(CN)COC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16288003 0.90
SCHEMBL1352530 0.85
SCHEMBL2848183 0.82
SCHEMBL6124696 0.80
Hydrochloric Acid SCHEMBL7962177 0.79 EPHX1 (0.35)
Bromide SCHEMBL1394599 0.79 EPHX1 (0.35)
SCHEMBL10626682 0.79
SCHEMBL16259516 0.79
Water SCHEMBL10625822 0.77 EPHX1 (0.33)
SCHEMBL11604099 0.77 EPHX1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12485109-B2 Pyrrolo 12.3-dipyrimidine compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2025-12-02 US disclosed
US-20250332138-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER VIVOZON, INC. (KR) 2025-10-30 US disclosed
US-12435051-B2 Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof VIVOZON, INC. (KR) 2025-10-07 US disclosed
US-20250034165-A1 COMPOUND CONTAINING CYCLOALKYL OR HALOALKYL CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2025-01-30 US disclosed
EP-4470534-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER Vivozon, Inc. (KR) 2024-12-04 EP disclosed
US-20240360092-A1 DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOF VIVOZON INC. (KR) 2024-10-31 US disclosed
EP-4442690-A1 COMPOUND CONTAINING CYCLOALKYL OR HALOALKYL Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2024-10-09 EP disclosed
US-12060339-B2 Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof VIVOZON INC. (KR) 2024-08-13 US disclosed
EP-3925956-B1 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BIOCRYST PHARM INC (US) 2024-04-10 EP disclosed
WO-2023146291-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER 주식회사 비보존 2023-08-03 WO disclosed
EP-2847177-A1 METHODS FOR MAKING OXETAN-3-YLMETHANAMINES Boehringer Ingelheim International GmbH (DE) 2015-03-18 EP disclosed
WO-2015013396-A1 CROSS-LINKABLE FLUORINATED PHOTOPOLYMER ORTHOGONAL, INC. (US) 2015-01-29 WO disclosed
US-20140349987-A1 PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORy, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES PHENEX PHARMACEUTICALS AG (DE) 2014-11-27 US disclosed
WO-2014039412-A1 PYRROLONE OR PYRROLIDINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-03-13 WO disclosed
WO-2013169531-A1 METHODS FOR MAKING OXETAN-3-YLMETHANAMINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-11-14 WO disclosed
US-8487099-B2 Gamma secretase modulators MERCK SHARP & DOHME CORP. (US) 2013-07-16 US disclosed
WO-2013053658-A1 COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2013-04-18 WO disclosed
US-20130090328-A1 COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE Hoffmann-La Roche Inc (US) 2013-04-11 US disclosed
US-20120107328-A1 GAMMA SECRETASE MODULATORS MERCK SHARP & DOHME CORP. 2012-05-03 US disclosed
EP-1834969-A2 Curable materials containing siloxane National Starch and Chemical Investment Holding Corporation (US) 2007-09-19 EP disclosed